rdf:type |
|
lifeskim:mentions |
|
pubmed:dateCreated |
1995-4-20
|
pubmed:abstractText |
We examined the effects of TCV-116, a non-peptide selective AT1 receptor antagonist, on cellular phenotype and on the expression of the transforming growth factor-beta 1 (TGF-beta 1) and extracellular matrix genes in the kidneys of stroke-prone spontaneously hypertensive rats (SHRSP). SHRSP were given vehicle or TCV-116 (10 mg/kg/day) by gastric gavage for 10 weeks (from the age of 22 to 32 weeks). Renal mRNA levels were measured by Northern blot analysis. In vehicle-treated 32-week-old SHRSP, urinary albumin excretion per 24 h was about 26-fold greater than that in age-matched Wistar-Kyoto (WKY) rats, and the mRNA levels of renal TGF-beta 1, fibronectin and collagen types I and III in SHRSP were all several-fold higher than those in WKY. Immunohistochemical studies showed the prominent presence of alpha-smooth muscle actin-expressing glomerular cells in SHRSP, in contrast to their absence in WKY. Treatment of SHRSP with TCV-116 decreased urinary albumin excretion and renal mRNA levels for TGF-beta 1 and for the above-mentioned extracellular matrix components. TCV-116 prevented the phenotypic modulation of glomerular cells in SHRSP. These results suggest that AT1 receptor antagonists may have powerful renal protective effects.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Biphenyl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Prodrugs,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Angiotensin,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta,
http://linkedlifedata.com/resource/pubmed/chemical/candesartan cilexetil
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0803-8023
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
54-6
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:7889201-Albuminuria,
pubmed-meshheading:7889201-Angiotensin II,
pubmed-meshheading:7889201-Angiotensin Receptor Antagonists,
pubmed-meshheading:7889201-Animals,
pubmed-meshheading:7889201-Antihypertensive Agents,
pubmed-meshheading:7889201-Benzimidazoles,
pubmed-meshheading:7889201-Biphenyl Compounds,
pubmed-meshheading:7889201-Cerebrovascular Disorders,
pubmed-meshheading:7889201-Extracellular Matrix,
pubmed-meshheading:7889201-Gene Expression,
pubmed-meshheading:7889201-Hypertension, Renal,
pubmed-meshheading:7889201-Kidney,
pubmed-meshheading:7889201-Kidney Glomerulus,
pubmed-meshheading:7889201-Male,
pubmed-meshheading:7889201-Phenotype,
pubmed-meshheading:7889201-Prodrugs,
pubmed-meshheading:7889201-RNA, Messenger,
pubmed-meshheading:7889201-Rats,
pubmed-meshheading:7889201-Rats, Inbred SHR,
pubmed-meshheading:7889201-Rats, Inbred WKY,
pubmed-meshheading:7889201-Receptors, Angiotensin,
pubmed-meshheading:7889201-Sclerosis,
pubmed-meshheading:7889201-Tetrazoles,
pubmed-meshheading:7889201-Transforming Growth Factor beta
|
pubmed:year |
1994
|
pubmed:articleTitle |
Renal protective effect of TCV-116 in stroke-prone spontaneously hypertensive rats.
|
pubmed:affiliation |
Department of Pharmacology, Osaka City University Medical School, Japan.
|
pubmed:publicationType |
Journal Article
|